These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27584023)

  • 1. Cancer immunotherapy: new applications in urologic oncology.
    Mullane SA; Bellmunt J
    Curr Opin Urol; 2016 Nov; 26(6):556-63. PubMed ID: 27584023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunotherapy in urological cancers.
    Bosnali E; Akdas EM; Telli E; Teke K; Kara O
    Arch Ital Urol Androl; 2024 May; 96(2):12307. PubMed ID: 38818794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complications of immuno-oncology care: what urologist should know.
    Grajales V; Martini A; Shore ND
    BJU Int; 2024 May; 133(5):524-531. PubMed ID: 38437876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving adoptive cellular therapies in urological malignancies.
    Wong YNS; Joshi K; Pule M; Peggs KS; Swanton C; Quezada SA; Linch M
    Lancet Oncol; 2017 Jun; 18(6):e341-e353. PubMed ID: 28593860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
    Mock A; Zschäbitz S; Kirsten R; Scheffler M; Wolf B; Herold-Mende C; Kramer R; Busch E; Jenzer M; Jäger D; Grüllich C
    Cancer Immunol Immunother; 2019 Dec; 68(12):2005-2014. PubMed ID: 31701161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urologic Oncology: Testis Cancer and Advances in Oncologic Therapy.
    Richie JP
    J Urol; 2023 Aug; 210(2):382-383. PubMed ID: 37199090
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimating the Size and Scope of the Urologic Oncology Clinical Trials Enterprise.
    Stensland KD; Krischak MK; Bank M; Sekar RR; Lewicki P; Piatt GA; Ghani K; Herrel LA; Barnes GD; Odell DD; Skolarus TA
    Urol Pract; 2024 Jul; 11(4):627-629. PubMed ID: 38899679
    [No Abstract]   [Full Text] [Related]  

  • 8. Metastasis-directed therapy among urological malignancies: where do we stand?
    Re C; Stewart GD; Capitanio U
    Curr Opin Urol; 2024 Jul; 34(4):258-260. PubMed ID: 38835186
    [No Abstract]   [Full Text] [Related]  

  • 9. Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions.
    Cigliola A; Prakash G; Li R; Oualla K; Gupta S; Kamat AM; Chahoud J; Necchi A; Spiess PE
    Curr Oncol Rep; 2024 Sep; 26(9):977-990. PubMed ID: 38847974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies.
    Skalina KA; Małachowska B; Sindhu KK; Thompson M; Nehlsen AD; Salgado LR; Dovey Z; Hasan S; Guha C; Tang J
    BJUI Compass; 2024 Mar; 5(3):334-344. PubMed ID: 38481668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care.
    Leapman MS
    Urol Pract; 2024 Jan; 11(1):7-8. PubMed ID: 37747948
    [No Abstract]   [Full Text] [Related]  

  • 12. Correction: Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies.
    Ma W; Shi Q; Zhang L; Qiu Z; Kuang T; Zhao K; Wang W
    BMC Cancer; 2024 Jul; 24(1):844. PubMed ID: 39014334
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy, a new approach for the treatment of human pain.
    Goode DJ
    Pain; 2024 Apr; 165(4):725-726. PubMed ID: 37975869
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer immunotherapy: new applications in urologic oncology.
    Hurwitz ME; Sokhn J; Petrylak DP
    Curr Opin Urol; 2016 Nov; 26(6):535-42. PubMed ID: 27584025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade in lung cancer.
    Somasundaram A; Socinski MA; Villaruz LC
    Discov Med; 2016 Aug; 22(119):55-65. PubMed ID: 27585231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
    Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
    Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.